26 February 2025
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Grant of
Options
Ondine Biomedical Inc. (LON: OBI), a
Canadian life sciences company pioneering light-activated
antimicrobial treatments, announces the grant of stock options to
two key executives as part of the Company's ongoing commitment to
attracting and retaining top-tier leadership.
On 25 February 2025, Ondine awarded
a total of 9,315,286 options to subscribe for new common shares in
the Company ("Options") to Dr. Nicolas Lobel, in recognition of his
significant contributions to the development and advancement of
Ondine's cutting-edge photodisinfection technology, and to Michael
Behlke as part of his long-term compensation package. Details of
the Options are as follows:
|
Director
|
Position
|
Options
granted
|
Exercise
price
|
Total options now
held
|
|
Dr. Nicolas Loebel
|
President & Chief Technology
Officer
|
6,000,000
|
11.25
pence
|
9,575,000
|
|
Michael Behlke
|
Chief Financial Officer & Chief
Operating Officer (PDMR)
|
3,315,286
|
11.25
pence
|
3,315,286
|
The Options all have an exercise
price of 11.25 pence, being the closing share price on 21 February
2025 (the "Approval Date"), the day on which the grant of Options
was approved by the Board. The Options vest evenly over a period of
3 years from the Grant Date, with a third vesting on each of the
three successive anniversaries of the Grant Date, and can be
exercised for a period of eight years from the Grant
Date.
Following the grant of Options, the
Company has 22,420,286 options to subscribe for new common shares
outstanding, which represents 5.07% of the Company's current issued
share capital.
The FCA notifications in respect of
the above Option grants, made in accordance with the requirements
of the UK Market Abuse Regulations, are appended below.
Carolyn Cross, Ondine's Chief Executive Officer,
commented:
"We are pleased to recognize the dedication and expertise of
our leadership team. These option grants mark a key step in
aligning leadership incentives with Ondine's long-term
success.
"As we continue to expand our global footprint and advance our
breakthrough infection prevention solutions, these options serve as
a reflection of our commitment to driving shareholder value and
attracting and retaining top talent."
The newly granted stock options will
vest over 3 years, ensuring continued alignment with the Company's
strategic objectives and long-term growth plans.
Enquiries, please contact:
|
Ondine Biomedical
Inc.
|
www.ondinebio.com
|
|
Carolyn Cross, CEO
|
Via Vane Percy &
Roberts
|
|
Strand Hanson Limited (Nominated & Financial
Adviser)
|
|
|
James Harris, Richard
Johnson
|
+44 (0)20 7409 3494
|
|
|
|
|
RBC
Capital Markets (Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a Canadian
life sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of
development.
Ondine's nasal photodisinfection
system has a CE mark in Europe and is approved in Canada and
several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1. Nicolas
Lobel
2. Michael
Behlke
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
1. President
and CTO (PDMR)
2. CFO and
COO (PDMR)
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Ondine Biomedical Inc.
|
|
b)
|
LEI
|
9845005B69E07CGF4A56
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Options to subscribe for Common
Shares
|
|
Identification code
|
ISIN: CA68234M2058
|
|
b)
|
Nature of the transaction
|
Grant of options to subscribe for
common shares of no par value
|
|
c)
|
Price(s) and volume(s)
|
|
PDMR
|
Price(s)
|
Volume(s)
|
|
Nicolas Lobel
|
Exercise price of 11.25
pence per share
|
6,000,000
|
|
Michael Behlke
|
Exercise price of 11.25
pence per share
|
3,315,286
|
|
|
d)
|
Aggregated information:
·Aggregated volume
·Price
|
N/A
|
|
e)
|
Date of the transaction
|
25 February 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
